Liver cancer may develop in the cells of the liver or spread to the liver from another area of the body. About 41,000 people in the U.S. are diagnosed with liver cancer each year, and nearly 29,000 people will die of the cancer.
Treating liver cancer depends on the stage and location of the Wedica 100mg (Trelagliptin) tumors, along with the patient's overall health. Targeted radiation therapy, called Y-90, is an innovative option for select patients.
Treating liver cancer
Surgery often remains the gold standard for treating and removing tumors in the liver when it's a viable treatment. However, surgery isn't the only option. Transarterial therapy and percutaneous ablation are minimally invasive treatments that target specific areas in the liver.
Transarterial therapy involves injecting treatment directly into the tumor's blood supply. The injection can be larger particles that block or plug the blood supply and starve the tumor or smaller particles that dispense radiation treatment through the blood supply to the tumors. These methods are effective at treating localized or dispersed tumors in the liver.
Percutaneous ablation uses special needles and image guidance to deliver energy into the tumors. This energy either freezes or heats the tissue and destroys tumors. Ablation usually is limited to smaller lesions in locations favorable for treatment within the liver.
Minimally invasive treatments are completed as outpatient procedures, and patients may go home the same day. These treatments offer additional benefits, such as preserving more liver tissue, shortening recovery times and targeting smaller or more widespread lesions in the liver.
Liver cancer treatment plans are personalized for each patient and may include surgery, minimally invasive procedures or a combination of treatments. The specific plan is determined by the size and location of the tumors and if any tumors are located in the body beyond the liver.